Clinicopathological profile of neuroendocrine tumors of gastrointestinal tract

Jeya Shambavi J.1,2, Narmadhar R.3, Rajalakshmi V.4, Kalaivani Selvi S.4*

1,2,4Assistant Professor, 3Professor, 1Aarudpadai Veedu Medical College, Kirumampakkam, Puducherry, 2Madras Medical College, Chennai, Tamil Nadu, 3ESIC Medical College & PGIMSR, Chennai, Tamil Nadu, 4Sri Manakula Vinayagar Medical College and Hospital, Puducherry, India

Abstract
Introduction: Neuroendocrine neoplasms are derived predominately from enterochromaffin or Kulchitsky's cells. The estimated prevalence of neuroendocrine tumors (NET) is 1 to 2 cases per 100,000 people, of which gastrointestinal tract (GIT) is the most common site. And being a rare tumor, it is less studied
Aim of the Study: To study the clinicopathological profile of Neuroendocrine tumors of GIT.
Materials and Methods: All specimens of neuroendocrine tumors received from the Department of Surgery and Department of digestive health diseases during the period from September 2008 to September 2012 were included. Clinical details were collected from the medical records in all cases. The tumors were classified based on WHO classification 2010 using morphological findings on H&E slides. Immunohistochemistry was done in 4 cases using Synaptophysin, Chromogranin and Neuron specific enolase.
Results: There were 886 neoplasms diagnosed in GIT of which 53 (5.98%) were NET. The mean age of presentation was 50 years. The male: Female ratio observed is 2:1. The most common presenting symptoms were abdominal pain followed by loss of appetite and weight. Carcinoid syndrome was seen in 2/53 (3.8%) patients. The most common site involved was Stomach followed by duodenum and ileum. NET Grade 1 was seen in 22 cases, NET Grade 2 was seen in 9 cases, NET Grade 3 was seen in 4 cases and mixed adenocarcinoma and neuroendocrine carcinoma (MANEC) was seen in 18 cases. Metastasis to liver was seen in 3 cases. Most of the NET tumors expressed the IHC markers, 95% were positive for NSE, 87.5% were positive for Synaptophysin and 82.5% cases were positive for Chromogranin.
Conclusion: Neuroendocrine tumors (NETs) are uncommon malignancies of GIT. Stomach was the most common anatomical site. NET grade 1 was the most common histological subtype. IHC markers NSE, Synaptophysin and chromogranin can be used in diagnosis of NETs.

Keywords: Neuroendocrine tumors, Gastrointestinal tract, Histomorphology, Immunohistochemistry, Grading.

Introduction
Neuroendocrine neoplasms are derived predominately from enterochromaffin or Kulchitsky's cells and have diverse pathologic findings that typically correspond to the site of origin and hormone-secreting ability.1 These tumors are found in the lung, ovary, and biliary and gastrointestinal tracts. The estimated prevalence of neuroendocrine tumors (NET) is 1 to 2 cases per 100,000 people, of which gastrointestinal tract (GIT) is the most common site.2 The incidence of GI – NET is around 67.5% amongst all NET.3 There are no epidemiological data regarding the incidence or prevalence of NET of GIT available from Indian literature. Among the various neuroendocrine tumors (NETs) in the gastrointestinal tract, the small intestine is the commonest site of occurrence and carcinoid tumor is the common pathological type.4,6 Neuroendocrine tumors include a spectrum of lesions that encompasses everything from carcinoid tumors (NET Grade 1), Atypical carcinoid / Intermediate neuroendocrine tumor (NET Grade 2) and neuroendocrine carcinomas (NET Grade 3). Majority of these Neuroendocrine tumors have an indolent course. Some are diagnosed incidentally while few have disseminated disease and may present as metastatic disease. Histological analysis often fails to distinguish the aggressive and metastatic potential of the tumor. Immunohistochemical stains such as chromogranins, synaptophysin and neuron specific enolase are used to identify neuroendocrine tumors and Ki 67 is used in grading the tumors into NET Grade 1, NET Grade 2, and NET Grade 3.5 In this study we have analyzed the clinicopathological, histomorphological and immunohistochemical study of neuroendocrine tumors of gastrointestinal tract.

Aims and Objectives
1. To evaluate the anatomical distribution of Neuroendocrine tumors of GIT.
2. To study the Histomorphological types of Neuroendocrine tumors of GI
3. To evaluate the expression of Immunohistochemical markers in NET.

Materials and Methods
This was a cross sectional descriptive study that included all specimens of neuroendocrine tumors received from the Department of Surgery and Department of digestive health diseases during the period from September 2008 to September 2012 were included. A detailed history regarding the age, sex,
clinical symptoms, site, were collected from the medical records in all cases.

The specimens were received and fixed in 10% neutral formalin for 18 - 24 hours and was sampled as per standard guidelines and submitted for processing. The tissues were processed in various grades of alcohol and xylol using automated histokinette and was stained for Haematoxylin and Eosin. The tumors were classified based on WHO classification 2010 using morphological findings on H&E slides.

Immunohistochemistry was done only in 40 cases. IHC could not be done in those cases where blocks could not be retrieved or where tissues had been exhausted. The immunohistochemical stains used were Synaptophysin, Chromogranin, and Neuron specific enolase.

**Immunohistochemical stains**
The following Immunohistochemical antibodies were used from the Biogenex laboratories.
1. Neuron specific enolase (NSE) used was Mouse monoclonal (MIG-N3).
2. Chromogranin A, Mouse Monoclonal (LK2H10), IgG1, Kappa
3. Synaptophysin, Mouse Snp 88, IgG3, Kappa.

Sections for Immunohistochemistry were taken on Slides coated with chrome alum. Sections were subjected to antigen retrieval using pressure cooker technique using citrate retrieval solution (pH 6) and then treated by Horse Radish Peroxidase (HRP) polymer techniques.

**Synaptophysin** showing cytoplasmic or membranous granular-brown staining was considered Positive

**Chromogranin and NSE:** showing cytoplasmic brown staining was considered Positive

Statistical analysis was done based on Microsoft excel version 2010. The frequency of all variables was analyzed.

**Observation and Results**
There were 886 neoplasm diagnosed in GIT totally during the five year period of study (September 2008 - September 2012) out of which 53 (5.98%) were neuroendocrine tumors. The age of the patients ranges from 25- 71 years with the mean age of presentation of 50 years.

The most common presenting symptoms were abdominal pain followed by loss of appetite and loss of weight and vomiting (chart-1). Carcinoid syndrome characterized by the complex of flushing, diarrhea, abdominal pain, and occasional asthma was seen in 2/53 (3.8%) patients.

**Chart 1: Clinical presentation of neuroendocrine tumors**

Out of 53 specimens 45 were biopsy specimens and 8 were resection specimens. The most common site involved was Stomach followed by duodenum and ileum, tabulated in Table 1.

### Table 1: Anatomical site and histomorphological grading of neuroendocrine tumors

| Site           | NET G1 | NET G2 | NEC | MANEC | Total no of cases n(%) |
|----------------|--------|--------|-----|-------|-----------------------|
| Oesophagus     | 1      | 0      | 0   | 0     | 1(1.9)                |
| Stomach        | 8      | 6      | 1   | 9     | 24(45.3)              |
| Small intestine| 10     | 2      | 1   | 5     | 18(34)                |
| Appendix       | 1      | 0      | 0   | 0     | 1(1.9)                |
| Colon          | 0      | 0      | 2   | 3     | 5(9.4)                |
| Rectum         | 2      | 1      | 0   | 1     | 4(7.5)                |
| Total n(%)     | 22(41.5)| 9(17)| 4(7.5)| 18(34)| 53(100)              |

On histopathological examination Neuroendocrine tumor G1 was seen in 22 cases, neuroendocrine tumor G2 was seen in 9 cases, NEC was seen 4 cases and MANEC was seen in 18 cases (Fig. 1). The distribution of different types of NET at various sites in GIT is tabulated in Table 1. Metastasis was seen in 3 cases and all cases were NET G3 and all showed metastasis to liver.
Neuroendocrine tumors are rare in paediatric age group.据Rothenstein J et al study and Amarapurkar DN et al study showed that Males were more commonly involved in Neuroendocrine tumors of GIT as seen in our study.8,10

The most common site in GIT in our study is the stomach. Our study correlated with Amarapurkar et al study conducted in India with stomach being the common site. Amarapurkar et al study also showed that next common site was small intestine followed by Rectum and colon. A study in Brazil by Bruna Estrozi et al also showed that the most common site was Stomach followed by small intestine.9 Whereas in a study by Borislav et al11 small intestine is the most common site with 52.6% followed by rectum and colon.

Hodgson et al12 in 2005 have shown statistically significant eight or nine fold increase in the incidence of gastric Neuroendocrine tumors. Modlin et al13 have shown significant increase in incidence of gastric neuroendocrine tumors from 2.4 to 8.7%. A study from India by Hegde et al has also shown rising incidence of gastric NETs as compared to the past.2 This increase can be attributed to widespread use of proton pump inhibitors or increased endoscopic surveillance with expertise in reporting gastric biopsies.2 The most common presenting symptom in our study was Abdominal pain which was comparable with Amarapurkar et al study.10 Other presenting symptoms were vomiting, loss of weight and appetite, diarrhea and bleeding per rectum.

In our study NET G1 was the most common histologic type followed by NET G2 and Neuroendocrine carcinomas respectively which correlates with literature where Rothenstein J et al and Amarapurkar et al also found NET G1 as the most common tumor.14,10

Carcinoid syndrome is frequently discussed in relation to carcinoid tumors. However, the complex of flushing, diarrhoea, abdominal pain, and occasional asthma or right-sided valvular problems is actually uncommon. Ito T et al and Soga J et al study also showed that less than 10% (1.7%–8.4%) of neuroendocrine tumors exhibit some of these symptoms.15,16 In a study conducted by Warrell et al. (2003) Carcinoid syndrome occurred in 10% of the cases.17 In our study there were only two cases (3.8%) of total as comparable with Amarapurkar DN et al study conducted in India with 4.1%. Both the cases were carcinoid tumors (NETG1) of appendix that presented with Carcinoid syndrome.

Matsui K et al and Okita NT et al showed malignant tumours with mixed glandular and neuroendocrine characteristics; with at least 30% of one component was seen in 34% of cases. They should be diagnosed because treatment depends on both the components.18,19

According to Matsui K et al18 and Okita NT et al19 neuroendocrine carcinoma is a rare tumor with highly malignant biological behavior exhibiting aggressive growth that leads to vascular invasion, distant...
metastasis and extremely poor prognosis. According to Rothenstein J et al.24 metastasis was observed in 53% of the cases. In a study by Amarapurkar et al.10 Metastasis was seen in 18.9% of cases but our study showed Metastasis in only 5.7% (3 cases) of the cases and all the three cases were NET G3 which showed metastasis to liver. Two of which were from stomach and one case was from small intestine. Immunohistochemical studies were used to confirm the diagnosis of neuroendocrinetumors. Our study also showed that most of the NET tumors expressed the IHC markers NSE and Synaptophysin compared to chromogranin. Anna Fen-Yau Li et al also found that NSE and Synaptophysin to be the most useful markers in confirming Neuroendocrine tumors.20

Conclusion

Neuroendocrine tumors (NETs) are uncommon malignancies of GIT. Stomach was the most common anatomical site. NET Grade 1 was the most common histological type. IHC markers NSE, Synaptophysin and Chromogranin can be used in diagnosis of NETs.

Funding: No funding sources.

Conflict of interest: None declared.

References

1. Ramage JK, Davies AH, Ardill J, et al. "Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours". Gut. 54 Suppl 4 / gut.2004.
2. Hegde V, Mohandas KM, Ramadwar M, Shukla P, Mehta S. Gastric carcinoids – a changing trend. Indian J Gastroenterol 2003;22:209–11.
3. Sippel RS, Chen H. Carcinoid tumors. Surg Oncol Clin N Am 2006;15:463–78.
4. Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004;240:117-22.
5. Modlin, I. M.; Shapiro, M. D.; Kidd, M. “Siegfried oberndorfer: Origins and perspectives of carcinoid tumors”. Human Pathol 2004;35(12):1440–51.
6. Radhakrishnam S, Subramoniam S. Colorectal carcinoids in South India. Trop Geog Med 1979;31:63–7.
7. OyvindHasso, MD, Bjorn I, Gustafsson, MD, PhD. Neuroendocrine Tumor Epidemiology American Cancer Society2008:2655-2664
8. Rothenstein J, Cleary SP, Pond GR, Dale D, Gallinger S, Moore MJ, Brierley J, Siu LL. Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital. Am J Clin Oncol 2008;31(1):64-70.
9. BrunaEstrozi, Carlos E. Bacchi Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases. Clinics 2011;66(10):1671-75.
10. Amarapurkar DN, Juneja MP, Patel ND, Amarapurkar AD, Amarapurkar PD. A retrospective clinicopathological analysis of neuroendocrine tumors of the gastrointestinal tract. Trop Gastroenterol 2010;31(2):101-4.
11. Borislav A Alexiev, Cinthia B Drachenberg, John C Papadimitriou, Endocrine tumors of the gastrointestinal tract and pancreas: grading, tumor size and proliferation index do not predict malignant behaviour Diagnostic Pathology 2007;1597:2-8
12. Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005;19:1610–2.
13. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004;99:23–32.
14. Rothenstein J, Cleary SP, Pond GR, Dale D, Gallinger S, Moore MJ, et al. Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital. Am J Clin Oncol 2008;31(1):64-70.
15. Ito T, Tanaka M, Sasano H, Osamura YR, Sasaki I, Kimura W, et al Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 2007;42:497–500.
16. Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res 1999;18:133–41.
17. Warrell et al. (2003). Oxford Textbook of Medicine (4th ed.). Oxford University Press
18. Matsui K, Kitagawa M, Miwa A, Kuroda Y, Tsuji M. Small cell carcinoma of the stomach: a clinicopathologic study of 17 cases. Am J Gastroenterol 1991;86:1167–75.
19. Okita NT, Kato K, Takahari D, Hirashima Y, Nakajima TE, Matsubara J, Hamaguchi T, Yamada Y, Shimada Y, and Taniguchi H, Shirao K. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 2011;14:161–65.
20. Anna Fen-Yau Li, Alice Chia-Heng Li. Small cell carcinomas in gastrointestinal tract: immunohistochemical and clinicopathological features. J Clin Pathol 2010;63:620-25.

How to cite this article: J. Jeya, R. Narmadhav, V. Rajalakshmi, S. Kalaivani. Clinicopathological profile of neuroendocrine tumors of gastrointestinal tract. J Diagn Pathol Oncol 2018;3(4):286-89.